Researchers have discovered a protein called Aurora-related kinase 1 (ARK1) that is vital for the malaria parasite's cell division. Disabling ARK1 in experiments halted the parasite's ability to replicate in both human and mosquito hosts. The finding, published in Nature Communications, highlights a potential target for new antimalarial drugs.
Malaria, caused by Plasmodium parasites, remains one of the world's deadliest infectious diseases, with the parasites multiplying rapidly inside human hosts and mosquitoes. A new study reveals how these parasites divide in an unusual way, distinct from human cells, relying on a specialized protein to manage the process.
The research, involving scientists from the University of Nottingham, the National Institute of Immunology in India, the University of Groningen in the Netherlands, the Francis Crick Institute, and other collaborators, centers on Aurora-related kinase 1 (ARK1). This protein functions as a cellular traffic controller, organizing the spindle structure that separates genetic material during the parasite's atypical mitosis.
In laboratory tests, disabling ARK1 disrupted spindle formation, preventing proper cell division. As a result, the parasites could not complete their life cycle in either humans or mosquitoes, breaking the transmission chain. The study was published in Nature Communications on March 4, 2026.
Dr. Ryuji Yanase, first author from the University of Nottingham's School of Life Sciences, stated, "The name 'Aurora' refers to the Roman goddess of dawn, and we believe this protein truly heralds a new beginning in our understanding of malaria cell biology."
Annu Nagar and Dr. Pushkar Sharma from the Biotechnology Research and Innovation Council-NII in New Delhi emphasized the collaborative effort: "Plasmodium divides via distinct processes in the human and mosquito host, it was well and truly a team effort, which allowed us to appreciate the role of ARK1 almost simultaneously in the two hosts and shed light on novel aspects of parasite biology."
Professor Rita Tewari noted the therapeutic potential: "What makes this discovery so exciting is that the malaria parasite's 'Aurora' complex is very different from the version found in human cells. This divergence is a huge advantage. It means we can potentially design drugs that target the parasite's ARK1 specifically, turning the lights out on malaria without harming the patient."
The divergence between the parasite's ARK1 and human equivalents offers a promising avenue for developing targeted treatments to disrupt malaria transmission.
